Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Exercise Training in Pregnancy for Obese Mothers

24 januari 2020 uppdaterad av: Norwegian University of Science and Technology

Exercise Training in Pregnancy. Good for the Mother - Good for the Child?

Observational studies demonstrate that overweight in pregnancy is a risk factor for adverse pregnancy outcomes as fetal macrosomia, prolonged labor, low Apgar score, shoulder dystocia, nerve plexus injuries, increased proportion of instrumental deliveries and perineal ruptures. There is a 2.6 fold risk for gestational diabetes mellitus (fourfold in morbidly obese women) and a recent study has shown that fetuses of obese mothers develop insulin resistance in uterus.

Main aims of this study are to assess if regular exercise in pregnancy among obese women can prevent or influence weight gain; impaired cardiac function in mother and fetus/newborn; impaired vascular function in mother; insulin resistance/sensitivity; body composition in mother and offspring; lumbopelvic pain; urinary and/or fecal incontinence; prolonged labor

Studieöversikt

Status

Avslutad

Betingelser

Intervention / Behandling

Detaljerad beskrivning

Women with a self-reported pre-pregnancy BMI of 28 or more will be eligible for our study. Woman are eligible if they are 18 years or older, with a singleton live fetus at an early (week 12-14) ultrasound scan. Exclusion criteria are pregnancy complications with high risk for preterm labour or diseases that could interfere with participation.

Primary outcome measure is weight increase based on weight measured at 14 weeks and immediately before labour. Assessments are done at baseline at 14 (12-18) weeks of pregnancy, and again in week 38, as well as 3 months postpartum. Some measurements are also done at other points in time. The maternal secondary outcome measurements include fasting glucose, glucose tolerance assessed by 2-h, 75 mg per-oral glucose tolerance test, insulin resistance assessed by HOMA-IR, weight, height, body composition estimated by skinfold measurements in pregnancy and by dual energy x-ray absorptiometry postpartum, blood markers, lumbopelvic pain, urin- and fecal incontinence, quality of life, psychological wellbeing, depression, and diet.

Studietyp

Interventionell

Inskrivning (Faktisk)

91

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Trondheim, Norge, 7489
        • Norwegian University of Science and Technology

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Kvinna

Beskrivning

Inclusion Criteria:

  • Pre-pregnancy body mass index of 28 or more
  • 18 years or more
  • singleton live fetus at the routine ultrasound scan

Exclusion Criteria:

  • high risk for preterm labor or diseases that could interfere with participation

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Förebyggande
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Exercise training
Supervised exercise training at the hospital during pregnancy: the women will attend at least 2 weekly sessions consisting of aerobic exercise (walking on treadmills), strength training (for upper body, back, abdomen and legs) as well as pelvic floor muscle exercises. Each session is 60 minutes and lead by a physiotherapist or experienced exercise physiologist. The women will also go through motivational interviewing sessions throughout the intervention period and are encouraged to do home exercise training in addition to the exercise at the hospital
Exercise training at the hospital
Andra namn:
  • Träning
Inget ingripande: Control
Usual care as provided by the health services in Norway. The investigators will not advice the women to be inactive

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Weight gain during pregnancy
Tidsram: From 14 weeks pregnancy to delivery
Measured in kg
From 14 weeks pregnancy to delivery

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Fasting glucose
Tidsram: From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Blood samples to determine the fasting glucose after an overnight fast (>10 hours)
From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Glucose tolerance
Tidsram: From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
2 hour 75 mg per-oral glucose tolerance test. Gestational diabetes is diagnosed as fasting glucose = or > 6.9 mmol/L or 2h concentration = or > 7.8 mmol/L.
From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Insulin resistance
Tidsram: From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Homeostasis model assessment (HOMA-IR)
From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Body composition
Tidsram: From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Skinfold measurements, done by an experienced investigator using Harpenden kaliper. At the 3 months postpartum testing, also dual energy x-ray absorptiometry (DEXA scan) will be used.
From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Blood markers for cardiovascular disease
Tidsram: From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Inflammation markers, cytokines (leptin, resistin, adiponectin, tnf-alfa). Blood will be collected and stored for later analyses.
From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Lumbopelvic pain
Tidsram: From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Clinical assessment (active straight leg raising, pelvic provocation test), and validated questionnaire.
From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Urin- and fecal incontinence
Tidsram: From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Pelvic floor muscle function will be assessed by clinical assessment and by 2D and 3D ultrasound. The prevalence and severity of urin- and fecal incontinence will also be assessed by a validated questionnaire
From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Quality of life
Tidsram: From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Validated questionnaire
From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Sleep
Tidsram: From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Epworth sleepiness scale
From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Physical activity
Tidsram: From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Level of physical activity will be assessed by activity registration (armbands) and by validated questionnaires
From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Diet
Tidsram: From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Validated questionnaire: Norkost
From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Offspring birth weight, length and head circumference
Tidsram: At delivery
As recorded by the hospital
At delivery
Delivery complications
Tidsram: At delivery
Vaginal or caesarean delivery, and recorded complications during the delivery
At delivery
Markers of inflammation and metabolism in cord blood
Tidsram: At delivery
Cord blood will be sampled and stored for later analysis of relevant markers of inflammation and metabolism (including resistin, leptin, adiponectin)
At delivery

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 september 2010

Primärt slutförande (Faktisk)

1 juni 2015

Avslutad studie (Faktisk)

1 juni 2016

Studieregistreringsdatum

Först inskickad

6 september 2010

Först inskickad som uppfyllde QC-kriterierna

17 november 2010

Första postat (Uppskatta)

18 november 2010

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

28 januari 2020

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

24 januari 2020

Senast verifierad

1 juni 2018

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • ETiP-Ob

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera